Protara Therapeutics, Inc. (NASDAQ:TARA) Receives $26.25 Consensus Price Target from Analysts

Protara Therapeutics, Inc. (NASDAQ:TARA) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $26.25.

Several analysts have recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Friday, July 17th. Oppenheimer boosted their price target on shares of Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a report on Wednesday, May 20th. UBS Group reaffirmed a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Finally, Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th.

Protara Therapeutics Stock Up 0.5%

Shares of NASDAQ:TARA opened at $4.12 on Tuesday. The business’s 50 day moving average is $4.06 and its 200 day moving average is $5.08. Protara Therapeutics has a 12-month low of $2.97 and a 12-month high of $7.82. The stock has a market cap of $231.56 million, a price-to-earnings ratio of -3.07 and a beta of 1.50.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. As a group, equities research analysts expect that Protara Therapeutics will post -1.44 earnings per share for the current year.

Institutional Trading of Protara Therapeutics

A number of hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC bought a new position in Protara Therapeutics in the 1st quarter valued at $8,454,000. UBS Group AG increased its position in shares of Protara Therapeutics by 44.2% during the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock valued at $6,479,000 after purchasing an additional 372,463 shares during the last quarter. Walleye Capital LLC raised its stake in shares of Protara Therapeutics by 204.0% during the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock worth $2,310,000 after purchasing an additional 297,525 shares during the period. Baker BROS. Advisors LP raised its stake in shares of Protara Therapeutics by 81.0% during the 4th quarter. Baker BROS. Advisors LP now owns 971,614 shares of the company’s stock worth $5,179,000 after purchasing an additional 434,782 shares during the period. Finally, Maven Securities LTD purchased a new position in shares of Protara Therapeutics in the 4th quarter worth about $4,022,000. 38.13% of the stock is currently owned by institutional investors.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.